Abstract | BACKGROUND: METHODS: Non-cirrhotic patients on LVD for at least 5 years with undetectable HBV DNA on at least two consecutive assessments were offered to stop treatment. Biochemical, serological and virological measures were determined at 3-6 month intervals after treatment discontinuation. Serum quantitative hepatitis B surface antigen ( HBsAg) was determined at treatment discontinuation and 5-6 years thereafter. NA treatment was re-instituted in patients with confirmed viral rebound defined as HBV DNA >20,000 IU/ml. Relapser patients were no longer followed but were re-assessed 6 years after treatment cessation. RESULTS: LVD was discontinued in 23 patients. 8 patients relapsed within 1 year and NA treatment was restarted; 15 patients (65%) were non-relapsers. Thirteen of them were followed for at least 5 years. Two patients had undetectable HBV DNA throughout the follow-up period. In the rest, HBV DNA fluctuated at low levels. Two patients cleared HBsAg 24 and 36 months after stopping treatment. Quantitative HBsAg levels 5-7 years after treatment discontinuation were lower in non-relapser compared to relapser patients (1.21 IU/ml ±0.98 versus 2.71 ±0.76; P=0.002). Of 8 relapser patients 1 patient had HBsAg levels less than 100 IU/ml compared to 11 out of 13 non-relapser patients (P=0.0022). CONCLUSIONS: These data suggest that cessation of NA treatment is a viable option after a reasonable treatment duration in patients with HBeAg-negative CHB and that HBsAg clearance may become an achievable target in these patients.
|
Authors | Fatih Karakaya, Sevil Özer, Çağdaş Kalkan, E Ali Tüzün, Aysun Çalışkan, Onur Keskin, Gökhan Kabaçam, Senem Karatayli, Ersin Karatayli, A Mithat Bozdayi, Ramazan Idilman, Cihan Yurdaydin |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 22
Issue 7
Pg. 559-570
( 2017)
ISSN: 2040-2058 [Electronic] England |
PMID | 28240596
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- Biomarkers
- DNA, Viral
- Hepatitis B Surface Antigens
- Hepatitis B e Antigens
- Lamivudine
|
Topics |
- Adult
- Aged
- Antiviral Agents
(adverse effects, therapeutic use)
- Biomarkers
- DNA, Viral
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepatitis B Surface Antigens
(blood)
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(immunology)
- Hepatitis B, Chronic
(blood, diagnosis, drug therapy, mortality)
- Humans
- Kaplan-Meier Estimate
- Lamivudine
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Time Factors
- Treatment Outcome
- Viral Load
|